With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
KVUE — frequently asked questions
Is Kenvue Inc. overvalued?
In our latest published analysis dated 2026-10-04, KVUE looks modestly undervalued. The price recorded at analysis is USD 17.2 versus our fair value of USD 18.2; the high endpoint is presented separately as potential value of USD 23.5. That implies roughly 5.6% upside to fair value at that date.
Our latest published report, analyzed 2026-10-04, gives KVUE a fair value of USD 18.2 and a potential value of USD 23.5. The conclusion is triangulated across multiple valuation models and weighted by reliability for Kenvue Inc.'s archetype; it is a dated research output, not a live price.
Should I buy KVUE now?
Our latest published rating for KVUE, analyzed 2026-10-04, is Hold. Kenvue Inc. looks modestly undervalued at the analysis-date price of USD 17.2 versus fair value of USD 18.2; potential value is USD 23.5. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for KVUE?
The dedicated bear-case section in our report analyzed 2026-10-04 documents Kenvue Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is KVUE's rating?
Our latest published rating for KVUE, analyzed 2026-10-04, is Hold, with a published moat assessment of 7.5/10 (Narrow). It reflects our fair value of USD 18.2, the potential value of USD 23.5, and the price recorded at analysis (USD 17.2).
Accelerated post-separation supply chain optimization and international expansion in EMEA ($3,721M) and Asia Pacific ($2,775M) could expand operating margins toward peer benchmarks near 18.0% to 20.97%, unlocking the bull casePotential value of $23.53 per share.
Main risk
Top retail customer order volume declines by more than 10% or demands promotional trade discounts exceeding 300 basis points.
We rate Kenvue Inc. Hold. At $17.20, the stock trades near its Fair value of $18.17, offering modest 5.6% upside alongside a dependable dividend as essential self-care cash flows balance debt service and retail channel concentration risks.4
The house rating is Hold. For an ordinary investor, a Hold rating indicates that the shares are fairly valued relative to the company's financial fundamentals and risk profile. Investors holding the stock should maintain their existing position rather than committing fresh capital or liquidating holdings, collecting the dependable dividend while monitoring operational execution and debt reduction.
The report was prepared at a price of $17.20 per share as of October 2, 2026. The house valuation establishes a Fair value midpoint of $18.17 per share and a Potential value of $23.53 per share. The report-date price of $17.20 sits 5.3% below Fair value, offering 5.6% upside to the central estimate. If operational efficiency and international volume acceleration exceed expectations, the stock could advance toward its Potential value of $23.53, representing 36.8% upside.4
The primary risk that would alter this view is customer concentration vulnerability combined with retailer margin pressure. Kenvue's largest retail partner accounts for 12% of consolidated net sales, or roughly $1,815M annually. If this customer initiates inventory destocking, reallocates shelf space to private-label goods, or demands steeper trade promotional discounts, Kenvue's operating margin could drop from 15.96% toward 13.0%. An investor would observe this through slowing North American volume growth, declining gross margins, and reduced operating cash flow available to service $8,524M in total balance-sheet debt.4,6,7
The primary driver that supports the investment case is the non-discretionary earning power of the Self Care franchise, which generated $6,378M in FY2025 sales. Essential over-the-counter healthcare products such as pain relievers and allergy treatments benefit from regular household replenishment and professional physician endorsements. This steady demand protects pricing power and gross margins above 58%. As operating cash flow of $2,197M comfortably funds modest capital spending of $475M, excess free cash flow accelerates balance-sheet deleveraging, expanding equity value per share over time.4,5,7
Non-Discretionary Self Care Brand Dominance
Kenvue's Self Care portfolio generates $6,378M in annual sales across OTC categories such as pain relief, allergy, and digestive health. Strong brand loyalty and doctor recommendations maintain inelastic consumer replenishment, supporting gross margins above 58%.5,7
With $2,197M in operating cash flow and disciplined capital spending of $475M in FY2025, Kenvue generates substantial free cash flow that reliably funds its $1,581M annual dividend while providing excess cash to pay down $8,524M in balance-sheet debt.4
Broad International Market Diversification
International operations account for 57.3% of total revenue across EMEA ($3,721M), Asia Pacific ($2,775M), and Latin America ($1,369M), shielding the company from single-region consumer weakness.
House recommendation
Hold: Kenvue's resilient self-care cash flows and dependable dividend are fairly priced at $17.20 against a Fair value of $18.17, with limited near-term multiple expansion upside given retail concentration and balance-sheet leverage.4
Company overview
Kenvue Inc. is a pure-play consumer health company operating globally across three reportable business segments: Self Care, Skin Health and Beauty, and Essential Health. The company markets widely recognized household brands including Tylenol, Zyrtec, Nicorette, Listerine, Aveeno, Neutrogena, Johnson's, and BAND-AID.
The Self Care segment offers products for cough, cold, allergy, pain care, digestive health, smoking cessation, and eye care. Skin Health and Beauty focuses on face and body care, hair care, and sun protection. Essential Health supplies oral care, baby care, women's health, and wound care solutions to consumers worldwide.
The company serves global consumer markets through mass merchants, supermarkets, and pharmacy retail channels, while managing operational compliance across regional consumer privacy, cybersecurity, and data protection regulatory frameworks.
Under a comprehensive downside stress test, Kenvue experiences a simultaneous contraction across channel demand, product pricing, and capital structure. If the primary retail customer (12% of revenue) cuts inventory order volumes by 15% and demands 300 bps of incremental promotional allowances, annual revenue declines by over $270M and operating margin compresses from 15.96% down toward 13.0%. Concurrently, private label penetration across US retail ($6,460M US sales) erodes volumes in Skin Health ($4,114M) and Essential Health ($4,632M). On the balance sheet, refinancing $2,750M of upcoming debt maturities at yields exceeding the pre-tax cost of debt of 6.06% increases annual interest expense by $40M to $60M, reducing net cash flow available for dividends ($1,581M paid in FY2025). In this scenario, equity value re-rates to the bear-case floor of $13.49, representing a 21.6% decline from the analysis price of $17.20.
Kenvue commands a narrow economic moat underpinned by durable intangible brand assets and entrenched retail distribution networks across consumer health. As the former consumer healthcare division of Johnson & Johnson, Kenvue holds premier global brand leadership across Self Care ($6,378M net sales in FY2025), Essential Health ($4,632M), and Skin Health and Beauty ($4,114M). These essential healthcare categories benefit from inelastic consumer demand, high household replenishment frequency, and strong physician and healthcare professional recommendations that insulate market share from cyclical economic downturns.
The company's distribution scale provides significant shelf-space advantages across multinational mass-market and pharmacy channels. In FY2025, Kenvue generated $15,124M in consolidated revenue, supported by substantial geographic diversification spanning North America ($7,259M), EMEA ($3,721M), Asia Pacific ($2,775M), and Latin America ($1,369M). While a single key customer accounts for 12% of total net sales, this stable channel alignment reflects high retail foot-traffic reliance on Kenvue's category-leading brands, preserving retail shelf dominance even as private label products expand.
However, the moat remains narrow rather than wide due to intense competition from large-scale consumer packaged goods peers such as Colgate-Palmolive (operating margin of 20.97%) and Procter & Gamble (operating margin of 22.09%), as well as growing private-label alternatives in skin health and personal hygiene. Furthermore, mass merchant buyer power constrains pricing realization and necessitates ongoing promotional allowances, bounding operating margin expansion at 16.0% to 17.0% relative to peer median profitability.
The highlighted cell is Fair value when every assumption sits at its base level ($18.17). Each row and column shows what Fair value becomes when one assumption moves.
Free cash flow to the firm stays positive in the first projected year at $1.5B after modeled reinvestment of $337.9M, with terminal value at 78.2% of enterprise value. A sudden drop in free cash flow is not projected unless capital spending relative to , reinvestment, or resets materially.
Upgrade the rating; Examine organic volume trajectory across international markets, verify sustained gross margin durability, and assess capacity for accelerated debt paydown relative to the capital return program.
Trigger: Consolidated revenue growth accelerating with Self Care organic expansion and operating margin expanding toward peer benchmark levels
Revenue outperformance driven by Self Care volume resilience and operating margin expansion toward peer levels would confirm accelerating post-separation efficiency gains, expanding free cash flow and justifying a rating upgrade.
In-line
Maintain Hold; Maintain position sizing, monitor quarterly cash conversion rates, track top retail partner order patterns, and evaluate progress on upcoming debt maturity refinancing.
Industry benchmark capital intensity reflects a mature, capital-disciplined operating environment, with industry capex-to-revenue of 1.1% (0.011) and capex-to-depreciation of 1.07. Kenvue's own capital expenditure of $475M in FY2025 represents 3.14% of revenue ($15,124M) and 0.85x of depreciation ($557M), confirming a steady-state reinvestment profile focused on maintenance rather than capacity expansion.6
Bull cycle
In an industry upcycle, consumer healthcare spending expands across OTC self-care and dermatological skin health, driven by household demand for clinical wellness products and demographic aging. Brand differentiation allows leading manufacturers to achieve pricing realization above inflation (2.0% to 3.5%) while maintaining volume growth. Retail partners expand shelf space allocations for premium personal care brands, and operating margins expand toward high-efficiency peer benchmarks such as Colgate-Palmolive (20.97% ) and Procter & Gamble (22.09%).
§11 Position management
Sizing
2-3%
Given the Hold rating, balanced risk-reward profile, and defensive dividend archetype, a 2-3% position weight in a diversified income portfolio is recommended for existing holders. Fresh capital deployment is not recommended until shares trade at a wider discount to Fair value ($18.17) or margin expansion accelerates.
Risk
Risk management focuses on monitoring retail channel health, private-label market share shifts, and debt maturity refinancing. Position size is capped at 3% of total portfolio value given the $8,524M debt load and customer concentration (12% of revenue). Quarterly checkpoints ensure immediate reassessment if operating margins breach 14.5% or top-customer alignment deteriorates below 9.0%.
§12 Investor perspectives
Income-Focused Investor
Hold
Kenvue delivers an attractive, dependable dividend backed by $2,197M in operating cash flow and modest maintenance capex of $475M, but high debt of $8,524M limits near-term dividend growth.4
Value / Fundamental Investor
Hold
The stock trades at $17.20, roughly in line with our Fair value of $18.17 (5.6% upside) and forward P/E of 14.73x. Without a wider discount to fair value or visible margin expansion toward peers like Colgate-Palmolive (20.97% margin), risk-reward remains neutral.3,4
Growth Investor
Avoid
Projected of 2.4% to 3.1% in FY2026-FY2027 reflects mature consumer staple dynamics rather than high growth, lagging peer leaders and offering limited organic top-line catalyst.
§14 Final recommendation
Action
Hold
Maintain existing equity holdings in Kenvue Inc. at the report-date price of $17.20. The stock trades at a modest 5.3% discount to our central Fair value of $18.17, offering 5.6% upside alongside a solid dividend yield. Inelastic demand across core Self Care brands ($6,378M revenue) supports operating cash generation of $2,197M, but elevated leverage ($8,524M debt) and channel concentration (12% top customer) warrant a balanced posture.4,7
Investors should collect the regular dividend while observing management's execution on post-separation supply chain efficiencies and upcoming debt refinancing. We recommend holding the position and reassessing if operational margin expansion accelerates toward high-performing peer benchmarks or if retailer destocking pressures materialize.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Analyst consensusData as of 2026-10-04 · Published 2026-10-04 · Provider-adjusted · cited for 2 figuresCited in Investor perspectives
Mass retail partner inventory destocking and aggressive trade allowance demands
Private-label encroachment eroding market share in skin health and personal care
Elevated interest expense on scheduled debt maturity refinancing
Constrained pricing power and margin compression across domestic distribution channels
The downside outcome materializes if primary retail partners execute inventory destocking while private-label substitutes gain market share across personal care categories. Stiffer competition limits pricing power, while higher refinancing rates on upcoming debt maturities increase interest burdens, depressing net operating margins and constraining capital allocation flexibility.
Ways this thesis can break
Top Retail Customer Destocking and Margin Squeeze
Kenvue's largest customer accounts for 12% of consolidated net sales ($1,815M of $15,124M total net sales in FY2025). Customer inventory destocking combined with aggressive demands for trade promotional discounts compresses operating margins from 15.96% down below 13.0%, impairing operating income.6,7
FV impact
-4%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Macro Rate Spike and Debt Refinancing Squeeze
Kenvue carries $8,524M in total debt against $1,062M in cash. With upcoming debt maturities of $750M in Year 1 and $1,000M in Year 3, higher refinancing rates push pre-tax cost of debt above 6.06% and elevate WACC by +200 bps over computed WACC of 7.1885%.2,4,6
FV impact
-22.1%
Cost of capital 2 points higher
Trigger
Within 18 months
Private Label Encroachment and Multiple Derating
In Skin Health ($4,114M revenue) and Essential Health ($4,632M), private label expansion erodes brand pricing power. The market derates Kenvue's exit P/E toward low-growth peer Kimberly-Clark (12.64x forward P/E), cutting the assumed 16.5x terminal multiple by 20% to below 13.2x.4,7
FV impact
-6.4%
Terminal multiple 20% lower
Early-warning signals to monitor
The five developments that would weaken our investment case.
Kenvue generates economic profits that exceed its cost of capital, supporting a narrow moat assessment. The company's ROIC of 10.70% comfortably exceeds its computed WACC of 7.1885% and computed moderate cost of equity of 7.8888%. While ROIC is constrained by $9,509M in goodwill and $19,156M in invested capital following the corporate separation from Johnson & Johnson, steady operating cash flows of $2,197M in FY2025 validate sustained cash generation above capital costs.2
7.5/ 10
Narrow
Sources of advantage
01Intangible Brand Assets and Healthcare Professional Recommendations — Kenvue's iconic OTC healthcare portfolio generated $6,378M in Self Care and $4,632M in Essential Health in FY2025, driving gross margin stability above 58% as demonstrated by Q2 2026 cost of revenue of $1,654M on $3,955M revenue.Wide
02Global Distribution Scale and Retail Shelf Integration — Consolidated sales of $15,124M across North America ($7,259M), EMEA ($3,721M), and APAC ($2,775M), alongside a durable 12% revenue partnership with its primary retail customer, create an entrenched omnichannel footprint that makes Kenvue essential to retailer foot traffic.Moderate
Private label substitution and peer promotional competition in Skin Health and Essential Health
medium
12-24 months
Continued R&D investment ($382M in FY2025), clinical validation, and healthcare professional recommendations defend consumer loyalty and support gross margins above 58%.
Retail channel concentration and mass merchant promotional allowance demands
medium
12-18 months
Category co-management, high SKU inventory turn rates, and category foot-traffic generation across essential OTC segments preserve bargaining power with the 12% revenue customer.7
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Stable revenue growth driven by steady consumer replenishment in essential health categories
Operating margins normalizing gradually with post-separation supply chain efficiencies
Steady retail shelf space allocation with primary distribution partners
Modest capital expenditure supporting disciplined debt service and dividend continuity
The base outcome assumes steady consumer replenishment in non-discretionary over-the-counter healthcare categories, maintaining predictable top-line progression and stable operating margins. Steady channel execution preserves shelf placement across mass retail partners while cash generation covers regular dividends and scheduled debt maturities. This modal path projects a target of $18.17 with an estimated probability of 55.0%, delivering an implied return of 5.6% against $17.20 (as of 2026-10-02).
In the bull outcome, brand reinvestment and strong clinical positioning accelerate organic revenue expansion across Self Care and international territories. Operating efficiencies expand operating margins toward peer benchmark levels, unlocking superior cash generation. At a target value of $23.53 carrying an estimated probability of 20.0%, this path offers an implied return of 36.8% relative to $17.20 (as of 2026-10-02).
Trigger: Revenue and diluted earnings tracking in line with consensus projections alongside stable operating margins
Financial results matching expectations demonstrate predictable demand across core consumer health franchises, maintaining fair value alignment near $18.17 without altering the risk-reward balance.
Miss
Downgrade the rating; Re-evaluate exposure to mass retail channels, review liquidity reserves against debt service obligations, and scrutinize consumer elasticity across discretionary skin health lines.
Trigger: Organic revenue contraction in core segments and operating margin compression below historical baseline levels
Top-line contraction resulting from retail inventory destocking or private label market share losses would degrade operating leverage, threatening dividend coverage and prompting a rating downgrade.
Earnings quality is supported by dependable cash generation, where operating cash flow substantially exceeds reported net income. Working capital requirements remain disciplined, and capital expenditures represent a modest fraction of sales, reflecting steady-state maintenance needs. Reported operating margins demonstrate recovery following initial separation costs, with minimal reliance on non-operating items or aggressive revenue recognition practices.
Estimate momentum
Consensus earnings and revenue estimates have remained steady following the recent quarterly earnings release, reflecting consistent operational delivery and well-anchored expectations across core self-care and essential health categories.
Metrics to watch into the print
01
Metric:
Self Care Organic Growth and Over-the-Counter Volume Trends
CurrentDemonstrating steady demand across essential healthcare categories, supported by physician recommendations and consistent household replenishment.
Why it matters
Self Care represents the largest share of revenue, so sustained organic volume growth protects pricing power, generates predictable cash flow, and preserves market share against competitive consumer staples.
02
Metric:
Primary Retail Customer Channel Stability
CurrentRevenue alignment with the largest retail customer has remained steady across recent fiscal years without channel disruption.
Why it matters
Channel alignment with the primary mass retail customer drives volume distribution, so any shift in inventory stocking policy directly alters operational overhead and net sales.
CurrentOperating profitability has recovered following post-separation transition costs, reflecting manufacturing efficiency and disciplined promotional spending.
Why it matters
Margin progress reveals whether standalone supply-chain separation initiatives are yielding operational leverage, directly influencing net operating profit after tax and reinvestment capacity.
CurrentBroad geographic distribution provides balanced revenue contributions across international territories alongside domestic North American operations.
Why it matters
International sales buffer regional economic softness, meaning sustained expansion across EMEA, APAC, and Latin America hedges domestic retail dependency and drives top-line durability.
05
Metric:
Free Cash Flow Generation and Balance Sheet Deleveraging
CurrentOperating cash flows exceed capital requirements, providing coverage for ongoing dividend distributions while supporting scheduled debt retirement.
Why it matters
Cash flow generation dictates capacity to service upcoming debt maturities and maintain regular dividend payments without escalating borrowing costs.
Kenvue's cash generation is a foundational pillar of its investment profile. In FY2025, operating cash flow of $2,197M provided robust 4.6x coverage of capital expenditures ($475M), producing $1,722M in free cash flow. This represents a substantial recovery from FY2024 ($1,335M FCF), driven by working capital stabilization and operating profit expansion. In Q2 2026, cost of revenue was $1,654M on revenue of $3,955M, maintaining gross margin resilience above 58%. The house forecast projects free cash flow to the firm of $1,539M in FY2026, rising to $1,823M by FY2030, supported by disciplined reinvestment rates between 15% and 18% of NOPAT.5
Capital allocation is heavily oriented toward shareholder dividends, reflecting Kenvue's mature dividend archetype. In FY2025, the company distributed $1,581M in common dividends, representing a payout ratio of 107.6% of GAAP net income ($1,470M) and 91.8% of free cash flow ($1,722M). Share repurchases were modest at $197M, roughly offsetting stock-based compensationdilution ($136M). Total debt of $8,524M and interest expense of $379M constrain aggressive capital return expansion. Management's capital priority remains maintaining the dividend, investing (3.14% of ), and directing excess cash toward debt paydown to lower before expanding buybacks.
ROIC recovered in FY2025 following corporate separation friction in FY2024, supported by operating income recovering to $2,414M on $15,124M revenue. Invested capital of $19,156M reflects substantial goodwill ($9,509M) from the J&J carve-out. Given steady-state capital expenditures ($475M in FY2025) and disciplined working capital, ROIC is projected to remain stable between 10.5% and 11.5% as operating margins normalize toward 16.5%–17.0%.
Kenvue's current ROIC of 10.70% comfortably exceeds its computed WACC of 7.1885% and moderate cost of equity of 7.8888%, generating an economic spread of approximately +351 bps over WACC.
Confirms that post-separation stranded overhead is subsiding, supporting house forecast projections of operating margins expanding to 16.2% in FY2026 and 17.0% by FY2029 without relying on unrealistic pricing acceleration.
Strong cash generation easily covers annual dividend payments ($1,581M paid in FY2025), leaving approximately $140M in discretionary free cash flow for debt retirement and modest buybacks ($197M in FY2025).
Debt Maturity Schedule and Refinancing Sensitivity
Kenvue carries $8,524M in total debt and $1,062M in cash ($7,462M net debt), with $750M due in year 1, $1,000M in year 3, and $1,000M in year 5 at pre-tax cost of debt of 6.06%.
Refinancing $2,750M of debt maturities under higher prevailing interest rates elevates interest expense above trailing $379M, capping capital return acceleration and reinforcing the Hold rating.
Kenvue Inc. (KVUE) trades at 14.7x forward earnings against a peer median of 20.1x. Its EV/EBITDA of 11.6x compares with a peer median of 14.7x. The comparison uses 4 peers: The Estee Lauder Companies Inc., Colgate-Palmolive Company, The Procter & Gamble Company and Kimberly-Clark Corporation, as of 2026-10-04.
In an industry downcycle, consumer spending pressures lead to widespread trade-down from branded OTC healthcare and personal care toward mass retailer private-label alternatives. Mass retail channels engage in aggressive inventory destocking, reduce safety stock levels, and demand higher promotional trade allowances to stimulate store foot traffic. Operating margins across consumer staples contract as input cost inflation cannot be fully passed through, while category growth stagnates below 1.0% YoY.
Secular trends
Trend
Impact
Note
Aging Demographics and Preventative Self-Care Expansion
positive
Global population aging and expanding consumer adoption of preventative self-care create steady structural volume replenishment across OTC analgesics, digestive health, and allergy categories, supporting Self Care ($6,378M).
Private-Label and Store-Brand Penetration in Mass Retail
negative
Retailers continue expanding high-quality private-label alternatives in commoditized personal hygiene and beauty lines, increasing competitive friction and promotional requirements in Skin Health ($4,114M) and Essential Health ($4,632M).
Mass Merchant Channel Integration and Omnichannel Healthcare Distribution
neutral
Consolidation of mass retail and pharmacy channels entrenches leading suppliers with massive retail shelf presence (such as Kenvue's 12% revenue customer), but also consolidates buyer purchasing power and restricts unconstrained pricing realization.
Positioning
Kenvue is positioned as a defensive, dividend-paying market leader in consumer healthcare. Its portfolio concentration in non-discretionary Self Care ($6,378M, 42.17% of FY2025 net sales) provides higher demand resilience than pure-play cosmetics or consumer packaged goods companies. However, Kenvue's operating margin of 15.96% lags top-tier peers like Colgate-Palmolive (20.97%) and Procter & Gamble (22.09%), indicating operational opportunity for post-separation cost rationalization alongside exposure to mass retailer promotional demands.3,7
Top retail customer order volume declines by more than 10% or demands promotional trade discounts exceeding 300 basis points. Kenvue's largest customer accounts for 12% of consolidated net sales ($1,815M of $15,124M net sales in FY2025). Severe customer inventory destocking and shelf reallocation toward private-label substitutes force heavy promotional concessions and order volume losses. Operating margins compress from 15.96% below 13.0%, reducing operating income by over $400M and lowering free cash flow, impairing debt repayment capacity and dividend safety. Quarterly operating margin falling below 13.00% or top retail customer revenue contribution dropping below 9.00% over two consecutive reporting periods.2,4,6,7
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Discounted forecast-period cash flows ($3.58) plus discounted terminal value ($12.80) minus signed net debt per current share ($3.88) equals the $12.49 lens value shown above. Negative net debt is net cash, so subtracting it raises value.
